Ardent Health (ARDT) Projected to Post Quarterly Earnings on Wednesday

Ardent Health (NYSE:ARDT) is projected to issue its Q4 2025 results after the market closes on Wednesday, March 4th. Analysts expect the company to announce earnings of $0.35 per share and revenue of $1.6312 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 10:00 AM ET.

Ardent Health Price Performance

Shares of ARDT opened at $9.49 on Tuesday. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of 6.54, a PEG ratio of 5.17 and a beta of 0.45. The firm’s fifty day simple moving average is $8.97 and its 200-day simple moving average is $11.07. Ardent Health has a twelve month low of $8.07 and a twelve month high of $15.55. The company has a current ratio of 2.08, a quick ratio of 1.95 and a debt-to-equity ratio of 0.67.

Key Stories Impacting Ardent Health

Here are the key news stories impacting Ardent Health this week:

• Positive Sentiment: Ardent confirmed participation in March investor conferences, giving management a platform to discuss strategy, operations and the company’s financial outlook — a potential confidence-builder for investors. Ardent Health to Participate in March Investor Conferences
• Neutral Sentiment: Multiple law firms have issued deadline reminders for investors to seek lead-plaintiff status in a securities class action (lead plaintiff deadline: March 9, 2026). These procedural notices increase attention and potential filings but do not by themselves change the merits of underlying claims. Representative notice: Rosen Law Firm. ARDT IMPORTANT DEADLINE: ROSEN
• Negative Sentiment: Hagens Berman and others are investigating/alleging material accounting issues tied to a Nov. 2025 disclosure about a “180‑day cliff” reserve approach and an alleged ~$97M accounting shock — allegations that raise questions about past receivables recognition and could hurt investor confidence and valuation. ARDT WRITE OFFS: Hagens Berman Investigating
• Negative Sentiment: Several national plaintiffs’ firms (Levi & Korsinsky, Schall, Glancy, Faruqi, BFA, Holzer and others) have filed or publicized class actions and investor notices covering purchases between July 18, 2024 and Nov. 12, 2025 — reinforcing legal risk and potential future litigation costs. Representative filing: Levi & Korsinsky. Contact Levi & Korsinsky by March 9, 2026 Deadline

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ARDT shares. UBS Group decreased their price target on Ardent Health from $14.50 to $14.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Truist Financial cut their price objective on shares of Ardent Health from $21.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, November 14th. Stephens reduced their price objective on shares of Ardent Health from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Friday, November 14th. Bank of America dropped their target price on shares of Ardent Health from $12.00 to $10.00 and set an “underperform” rating on the stock in a research report on Thursday, November 13th. Finally, Guggenheim dropped their price objective on Ardent Health from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $14.58.

Institutional Trading of Ardent Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARDT. VARCOV Co. purchased a new stake in shares of Ardent Health in the fourth quarter valued at about $232,000. Wells Fargo & Company MN raised its holdings in Ardent Health by 29.1% during the fourth quarter. Wells Fargo & Company MN now owns 25,963 shares of the company’s stock worth $229,000 after purchasing an additional 5,858 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Ardent Health in the fourth quarter valued at about $228,000. WINTON GROUP Ltd purchased a new stake in Ardent Health in the 2nd quarter valued at approximately $228,000. Finally, Alliancebernstein L.P. boosted its holdings in Ardent Health by 24.8% in the 3rd quarter. Alliancebernstein L.P. now owns 16,472 shares of the company’s stock valued at $218,000 after purchasing an additional 3,272 shares in the last quarter.

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.